TB-500 sits alongside BPC-157 as one of the two most-discussed compounds in the research-peptide recovery world. It is promoted for healing, tissue repair and inflammation. As with most of this market, the honest picture is narrower than the marketing — and it begins with a distinction the marketing tends to blur.
What it actually is
Here is the distinction the marketing rarely makes clearly. The natural protein is thymosin beta-4 — a 43-amino-acid peptide found throughout the body, with roles in cell migration, wound healing and cardiac repair. The compound sold online as TB-500 is not the same molecule. It is a much shorter peptide — typically the 7-amino-acid fragment LKKTETQ, the actin-binding region of the parent. It was originally developed as a tool compound for veterinary research.
Like BPC-157, it is sold "research use only" and is not an approved medicine for human use.
What the research actually shows
The distinction above is the whole point: most of the published clinical evidence cited as supporting "TB-500" actually relates to the full-length thymosin beta-4 molecule, not the truncated fragment sold to consumers. The most advanced clinical programme, RGN-259, is a topical eye-drop formulation studied for dry eye and corneal injury — not the injectable fragment associated with sports recovery.
For the LKKTETQ fragment actually sold as TB-500, the human evidence is very limited: a couple of small trials in topical wound applications, and no completed Phase 2 or Phase 3 trials for systemic injectable use in musculoskeletal indications. The marketing, in effect, borrows credibility from the parent molecule's research without that evidence transferring as cleanly as implied.
Where it stands with regulators
TB-500 is not approved by any medicines regulator for human use. The FDA placed it in Category 2 of the bulk drug substances list in 2023, alongside BPC-157, and removed it from that category in April 2026 — a reclassification, not an approval. In the UK, the MHRA does not license it and supply for human use is unlawful. The World Anti-Doping Agency has banned thymosin beta-4 (and by extension TB-500) since 1 January 2012.
And as with the rest of the unregulated market, the molecule actually in the vial may or may not be what the label claims.
The honest summary
- TB-500 is the 7-amino-acid fragment LKKTETQ — not the full 43-amino-acid thymosin beta-4.
- Most cited clinical evidence is for the full protein (e.g. RGN-259 eye drops), not the injectable fragment.
- No completed Phase 2/3 human trials for systemic injectable use in musculoskeletal indications.
- Not an approved medicine; WADA-banned since January 2012; product identity often uncertain.
The sober bottom line
TB-500 is a compound where the most important fact is a distinction the marketing erases — between the full protein the science studied and the fragment people actually buy. It is interesting, it is unapproved, and the human evidence for the thing being sold is very thin. That is exactly the kind of gap the book is written to make visible.
The full chapter is in the book.
This page summarises a fraction of what Peptides: A Sober View covers on TB-500 — the full compound profile, the thymosin beta-4 distinction, the cited literature, and where it sits in the wider research-peptide market.
Get the book — £14.99